CureVac N.V.
curevac.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2024 20-F, filed Apr 11, 2025. Its latest SEC filing is a 15-12G from Jan 16, 2026.
20-F for FY2024, filed Apr 11, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops mRNA-based vaccine and treatment candidates for infectious diseases, cancer and other conditions with collaboration partners.
20-F for FY2024, filed Apr 11, 2025
Who Were Their Customers?
Collaboration partners buy access to CureVac’s mRNA technology, research and development services, and product deliveries through licensing and development agreements.
20-F for FY2024, filed Apr 11, 2025The Group primarily generates revenue from its licensing and development agreements with its customers, which include collaboration…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 30.3% of its revenue as net income in .
20-F for FY2024, filed Apr 11, 2025
20-F for FY2024, filed Apr 11, 2025
EUR 162.2MView ↗
Who Did They Compete With?
Competes with BioNTech, Pfizer, Moderna, eTheRNA Immunotherapies, Translate Bio, GlaxoSmithKline, Sanofi, AstraZeneca, Merck &, Arcturus Therapeutics, Ethris, and Genevant Sciences
20-F for FY2024, filed Apr 11, 2025There are additional companies that are working on potential mRNA medicines. Companies with clinical programs with mRNA include…View ↗
Loading...
